Search Within

Azeez Farooki

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
  3. Guidelines (1)
Groups
  1. Department of Medicine (8)
  2. Division of Subspecialty Medicine (8)
  3. Endocrinology (8)
  4. Population Sciences Research Program (8)
  5. Survivorship Research (8)
  6. Epidemiology and Biostatistics (6)

More Groups

People
  1. Aaron Mitchell (5)
  2. Michael Morris (5)
  3. Akriti Mishra (3)
  4. Sonia Persaud (3)
  5. Allison Lipitz Snyderman (2)
  6. Jamie Ostroff (2)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (3)
  4. 2019 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. Clinical Lymphoma, Myeloma and Leukemia (2)
  3. JCO Oncology Practice (1)
  4. Prostate (1)
  5. Prostate Cancer and Prostatic Diseases (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier Inc. (2)
  3. John Wiley & Sons (1)
  4. Nature Publishing Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Costs to Medicare of nonrecommended bone-modifying agent use for castration-sensitive prostate cancer
    Journal Article

    Mitchell, A. P.; Nemirovsky, D.; Mishra Meza, A.; Chakraborty, N.; Persaud, S.; Farooki, A.; Morris, M. J.
    JCO Oncology Practice (2024)

    Fulltext@MSK | Save
  • Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer
    Journal Article

    Mitchell, A. P.; Persaud, S.; Palyca, P.; Salner, A.; Farooki, A.; Ostroff, J. S.; Morris, M. J.; Chimonas, S.
    Prostate (2024)

    Fulltext@MSK | Save
  • Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer
    Journal Article

    Mitchell, A. P.; Mishra Meza, A.; Panageas, K. S.; Lipitz-Snyderman, A.; Farooki, A.; Morris, M. J.
    Prostate Cancer and Prostatic Diseases (2023)

    Fulltext@MSK | Save
  • Barriers to guideline-concordant use of bone modifying agents for prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Persaud, S.; Chimonas, S.; Salner, A. L.; Palyca, P.; Farooki, A.; Ostroff, J. S.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Shen, S.; Salehi, E.; Farooki, A.; Flory, J.; Williams, D.; Carpio, A.; Chang, C.; Lacouture, M. E.; Andreopoulou, E.; Sardesai, S. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Use of bone modifying agents for metastatic castrate-resistant prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Mishra Meza, A.; Farooki, A.; Panageas, K.; Bach, P. B.; Lipitz-Snyderman, A.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas
    Guidelines

    Cheson, B. D.; O'Brien, S.; Ewer, M. S.; Goncalves, M. D.; Farooki, A.; Lenz, G.; Yu, A.; Fisher, R. I.; Zinzani, P. L.; Dreyling, M.
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save